Drug intelligence / Profile preview

GSK 208108

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Inhalation

Overview

GSK 208108 is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that was developed by GSK for the acute treatment of migraine. Uniquely among CGRP antagonists, it was formulated for delivery via inhalation to achieve rapid systemic absorption and fast onset of therapeutic effect, bypassing the gastrointestinal tract. The compound was evaluated in Phase 1 clinical trials to assess safety, tolerability, and pharmacokinetics, but development was ultimately discontinued by the sponsor.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on GSK 208108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK 208108.

Explore the full profile